Toggle navigation
Home
Search
Services
Blog
Contact
About
Preclinical Efficacy and Intermediate Endpoint Assays
Search grants from
Share this grant:
:
:
Abstract
Funding
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
The role of sweet taste genes in postingestive endocrine responses to sweeteners
Fatty Acids and Major Cardiovascular Outcomes
Evaluation of Taurine and Niacin in Lung Fibrosis
Islets Encapsulated in Photopolymerizable Alginate
Comprehensive Integration of Advanced Manufacturing Competencies throughout an Associates Degree and a Stackable Certificate Curricula
Recently added grants:
Mannose binding lectin-dependent complement activation in emphysema
In Vivo Regulation of Factor IXa by Protein S in Hemophilia and Systemic Hypercoagulability
Targeting the compromised brain endothelial barrier function during cerebral malaria with AT2 receptor agonists
Title: Neurobiology of seizure generalization during electroconvulsive therapy for major depression
Development of chemical biology tools for NMDA receptors
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN43309-8-0-1
Application #
7587179
Study Section
Project Start
2004-05-15
Project End
2009-05-14
Budget Start
Budget End
Support Year
Fiscal Year
2007
Total Cost
Indirect Cost
Related projects
NIH 2008
N01 CA
Preclinical Efficacy and Intermediate Endpoint Assays
/ Fox Chase Cancer Center
$2,364,525
NIH 2007
N01 CA
Preclinical Efficacy and Intermediate Biomarker Assays
Clapper, Margie /
$1,632,611
NIH 2007
N01 CA
Preclinical Efficacy and Intermediate Endpoint Assays
/
Comments
Be the first to comment on this grant